Ductus-Dependent Heart Defects: Prostaglandin E1 in the Emergency Setting

Few situations in neonatology are as time-critical as the impending closure of the ductus arteriosus in a neonate with a ductus-dependent heart defect. What was compensated during fetal life through open shunt connections becomes a life-threatening circulatory crisis within hours to a few days after birth. Timely administration of prostaglandin E1 (PGE1, alprostadil) determines life or death in these cases – and it is one of the few interventions in emergency medicine that can completely reverse a seemingly hopeless situation. This article provides you with the knowledge needed to recognize these children, initiate therapy, and safely stabilize them until pediatric cardiology care is available.

Pathophysiological Fundamentals

The Ductus Arteriosus – From Lifesaver to Problem

The ductus arteriosus Botalli is a fetal vascular connection between the pulmonary trunk and the descending aorta. In utero, it diverts the majority of right ventricular output past the non-ventilated lungs directly into the aorta. After birth, the rising partial pressure of oxygen together with the decline in circulating prostaglandins (following loss of placental production) leads to functional closure of the ductus – physiologically within the first 24–72 hours of life.

In a number of congenital heart defects, however, this closure is catastrophic because the ductus represents the only or essential connection through which either:

• the pulmonary vascular bed is perfused (ductus-dependent pulmonary perfusion), or
• systemic perfusion is maintained (ductus-dependent systemic perfusion), or
• mixing between oxygenated and deoxygenated blood occurs.

Classification of Ductus-Dependent Lesions

Ductus-dependent pulmonary perfusion (right-to-left shunt through the ductus supplies the lungs):

• Pulmonary atresia with and without VSD
• Critical pulmonary stenosis
• Tricuspid atresia with restrictive VSD
• Tetralogy of Fallot with severe outflow obstruction
• Certain forms of Ebstein's anomaly

Ductus-dependent systemic perfusion (left-to-right shunt through the ductus supplies the descending aorta):

• Hypoplastic left heart syndrome (HLHS)
• Critical aortic stenosis
• Interrupted aortic arch (IAA)
• Critical coarctation of the aorta

Ductus-dependent mixing:

• Transposition of the great arteries (TGA) – here the ductus is not the only level of mixing, but it can significantly improve oxygenation until a Rashkind maneuver (balloon atrial septostomy) is performed.

Recognizing the Clinical Presentation

The key lies in thinking of this diagnosis before the child is in extremis. Symptoms typically appear when the ductus begins to close – usually on the second to third day of life, but sometimes not until one to two weeks.

Warning Signs in Ductus-Dependent Pulmonary Perfusion

Here pulmonary blood flow is lacking, and the cardinal symptom is central cyanosis:

• Profound cyanosis that does not or barely responds to supplemental oxygen (a hallmark feature!)
• Tachypnea, but often without severe dyspnea (the lungs themselves are healthy)
• Pulse oximetry: SpO₂ values between 40–70% that barely improve even under 100% O₂
• Over time: metabolic acidosis, rising lactate

Warning Signs in Ductus-Dependent Systemic Perfusion

Here systemic perfusion is lacking – the child presents as if in cardiogenic shock:

• Gray-pale skin color, mottled, diaphoretic
• Weak or absent femoral pulses (particularly in coarctation and IAA)
• Tachycardia, tachypnea
• Hepatomegaly
• Oliguria to anuria
• Rapidly progressive metabolic acidosis, lactate often > 10 mmol/L
• Blood pressure difference between upper and lower extremities (> 10 mmHg systolic, in coarctation/IAA)

The Hyperoxia Test as a Diagnostic Tool

A simple yet valuable tool for distinguishing pulmonary from cardiac cyanosis is the hyperoxia test:

• The neonate is ventilated/provided with 100% O₂ for 10 minutes
• Pulmonary cause: PaO₂ typically rises well above 150 mmHg
• Cardiac cause (right-to-left shunt): PaO₂ typically remains below 100 mmHg, often below 60 mmHg
• Caution: Mixed lesions may produce intermediate values

Additionally, pre- and post-ductal pulse oximetry screening is essential: A saturation difference > 3% between the right hand (pre-ductal) and foot (post-ductal) is suspicious for a ductus-dependent heart defect or persistent pulmonary hypertension.

Prostaglandin E1 – Pharmacology and Dosing

Mechanism of Action

Alprostadil (prostaglandin E1) acts directly on the smooth muscle of the ductal wall. It binds to EP₂ and EP₄ receptors and produces dilation or reopening of the ductus arteriosus through cAMP-mediated relaxation. The effect typically occurs within 15–30 minutes, although in an already closed ductus it may take longer or, in rare cases, be ineffective.

Dosing

Prostaglandin E1 is administered as a continuous intravenous infusion (alternatively via an umbilical venous catheter):

Situation	Dosing
Starting dose	0.01–0.05 µg/kg/min
Acute emergency (child in extremis)	Start with 0.05–0.1 µg/kg/min
Maintenance dose (after response)	0.01–0.02 µg/kg/min (titrate to lowest effective dose)

Practical preparation (example):

• Draw up 1 ampoule of alprostadil (500 µg) in 50 mL of 0.9% NaCl → concentration: 10 µg/mL
• For a 3.5 kg neonate at a target dose of 0.05 µg/kg/min:
  • 0.05 × 3.5 = 0.175 µg/min = 0.0175 mL/min = 1.05 mL/h

Important: Different institutions and countries use different preparation standards. Always use the standardized dilutions and dosing tables established at your institution to avoid errors.

Therapeutic Goals

• In ductus-dependent pulmonary perfusion: Increase in SpO₂ to 75–85% (higher is not necessary – these children have single-ventricle physiology or parallel circulations)
• In ductus-dependent systemic perfusion: Improvement of peripheral perfusion, resolution of metabolic acidosis, palpable femoral pulses, increased urine output

Side Effects and Complication Management

PGE1 is a highly effective but side-effect-prone medication. You need to be prepared for the following complications:

Apnea – The Most Common and Most Dangerous Side Effect

• Occurs in 10–12% of neonates, especially in preterm infants and at higher doses
• Typically within the first hour after initiation of therapy
• Consequence: Readiness for intubation is mandatory! Appropriately sized equipment and a person with intubation competency must be immediately available
• Many centers recommend prophylactic intubation before a planned transport under PGE1

Other Side Effects

• Hypotension: PGE1 is a potent vasodilator. Have volume boluses (10 mL/kg 0.9% NaCl) and catecholamines ready if needed
• Fever/temperature instability: Common, due to PGE1 effect on the thermoregulatory center – not a reason to stop the infusion
• Bradycardia: Less common but relevant – monitoring is mandatory
• Thrombocytopenia: With prolonged use
• Cortical hyperostosis: Only relevant with long-term therapy over weeks
• Necrotizing enterocolitis (NEC): Rare but reported, especially in ductus-dependent systemic perfusion with already compromised mesenteric perfusion

Stabilization Until Pediatric Cardiology Care

Initial Measures – A Structured Approach

If you suspect a ductus-dependent heart defect, follow this structured approach:

1. Secure the airway, optimize oxygenation

   • Use oxygen cautiously: In ductus-dependent systemic perfusion, too much O₂ can lower pulmonary vascular resistance and cause a "pulmonary steal" phenomenon → target SpO₂ 75–85%
   • Ensure readiness for intubation (due to apnea risk under PGE1)

2. Establish venous access

   • Peripheral IV catheter or umbilical venous catheter
   • Umbilical venous catheter has the advantage of rapid access and reliable PGE1 administration

3. Start PGE1 infusion

   • Starting dose 0.05 µg/kg/min in a clinically unstable child
   • Expect clinical response within 15–30 minutes

4. Establish monitoring

   • Pre- and post-ductal pulse oximetry (right hand + foot)
   • ECG monitoring
   • Blood pressure measurement on all four extremities (if possible)
   • Temperature

5. Laboratory workup

   • Blood gas analysis (arterial or capillary): pH, lactate, base excess
   • Blood glucose (neonates are at risk for hypoglycemia!)
   • Complete blood count, electrolytes, creatinine
   • Blood type and crossmatch (in case of surgery)

6. Request echocardiography

   • Definitive diagnosis is made echocardiographically
   • If echocardiography is not available on site: Do NOT delay PGE1 administration when there is a well-founded suspicion!

7. Contact the pediatric cardiac center

   • Consult early
   • Organize transport under PGE1 infusion

Dos and Don'ts During Stabilization

Dos:

• Start PGE1 when there is well-founded clinical suspicion – better once too often than too late
• Ensure readiness for intubation before PGE1 is running
• Ensure thermal protection (neonates cool down rapidly)
• Inform parents – even in the emergency situation
• Think of associated pathologies: hypoglycemia, hypocalcemia, coagulopathy

Don'ts:

• Blindly apply high-dose oxygen when ductus-dependent systemic perfusion is suspected
• Prematurely discontinue PGE1 because of side effects (fever, mild hypotension)
• Wait for echocardiography before starting PGE1 when the child is clinically decompensating
• Send the child on transport without the capability to intubate

Don't Forget the Differential Diagnoses

Not every cyanotic or shocked neonate has a heart defect. Before fixating on a cardiac diagnosis, consider the following differentials:

• Neonatal sepsis – can look identical (gray, mottled, metabolic acidosis). When in doubt: start PGE1 AND treat with antibiotics
• Persistent pulmonary hypertension of the newborn (PPHN) – here oxygen often helps more effectively, and pulse oximetry typically shows a pre-/post-ductal difference
• Pneumothorax – rule out clinically and sonographically
• Metabolic diseases – e.g., congenital adrenal hyperplasia (salt-wasting crisis), inborn errors of metabolism
• Non-ductus-dependent heart defects – e.g., total anomalous pulmonary venous return with obstruction (PGE1 does not help here and may even be harmful)

A pragmatic approach in the acute setting: If a neonate in the first days of life presents with refractory cyanosis or cardiogenic shock, start PGE1, simultaneously initiate empiric antibiotic therapy, and actively search for treatable causes.

Special Considerations in Transposition of the Great Arteries

TGA occupies a special position: here two parallel circulations exist that are incompatible with life without mixing. The ductus alone is often insufficient for adequate mixing – the foramen ovale and any VSD present are frequently the critical connections.

• PGE1 can improve the situation but may not be sufficient
• In persistent severe cyanosis despite PGE1: Rashkind balloon atrial septostomy (emergency BAS) – this must be performed at a pediatric cardiac center
• Transport is particularly urgent in this scenario

Documentation and Handover

The following information is essential for handover to the pediatric cardiac center or transport team:

• Timing of symptom onset and clinical course
• Pre- and post-ductal saturation values (before and after PGE1)
• PGE1 dose and response (documented with timestamps)
• Airway status: spontaneously breathing or intubated, FiO₂
• Current blood gas values including lactate
• Volume status: boluses administered, urine output
• Echocardiography findings (if available)

Practical Training

Ductus-dependent heart defects are among the rare but highly critical situations in neonatal care. The decision to administer PGE1, management of apnea as a side effect, and structured stabilization until transport are best trained in realistic simulation scenarios. In the PALS course by Simulation Tirol – following American Heart Association guidelines – you practice exactly these scenarios hands-on as a team: from recognizing the critically ill neonate, through pharmacological therapy, to structured handover. This way, you are prepared when it truly matters.